YKL-40 and Complications in Type 2 Diabetes
Type 2 Diabetes Mellitus
|Study Design:||Observational Model: Case-Only
Time Perspective: Cross-Sectional
|Official Title:||Association Study of the Plasma Concentration of YKL-40 and Vascular Complications in Patients With Type 2 Diabetes|
|Study Start Date:||April 2010|
|Study Completion Date:||April 2010|
|Primary Completion Date:||April 2010 (Final data collection date for primary outcome measure)|
|Type 2 diabetes mellitus|
It is well recognized now that diabetes mellitus is a systemic vasculopathy and causes various micro- and macrovascular complications. Vascular damage and endothelium dysfunction in diabetes mellitus involve a chronic inflammatory process via a complicated mechanism.
YKL-40 is a 40 kD lectin molecule. It is secreted by various cells, including macrophages, vascular smooth muscle cells and giant cells, and the level of YKL-40 is found elevated in both acute (eg. infection) and chronic (eg. rheumatoid arthritis, systemic lupus erythematosus or cirrhosis of the liver) inflammatory processes. The plasma concentration of YKL-40 is elevated in the patients of type 2 diabetes mellitus compared with non-diabetic controls, and is associated with insulin resistance, fasting plasma glucose and plasma IL-6 concentrations. Furthermore, the concentration of YKL-40 is elevated and is associated with the severity of albuminuria in the patients of type 1 diabetes.
The objective of this study is to establish the relationship between plasma concentration of YKL-40 with various vascular complications in the patients of type 2 diabetes, and to evaluate its potential as a biomarker for the vascular diabetic complications in patients with type 2 diabetes.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01387984
|National Taiwan University Hospital Yun-Lin Branch|
|Douliu City, Yunlin County, Taiwan, 640|
|Principal Investigator:||Chih-Hung Lin, M.D.||National Taiwan University Hospital, Yun-Lin Branch|